Cargando…

Natural history of nonalcoholic fatty liver disease: A prospective follow‐up study with serial biopsies

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in the world. The complete natural history of NAFLD is unknown because few high‐quality follow‐up studies have been conducted. Our aim was to find variables predicting disease severity through an extended follow‐up...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nasr, Patrik, Ignatova, Simone, Kechagias, Stergios, Ekstedt, Mattias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796332/ https://www.ncbi.nlm.nih.gov/pubmed/29404527 http://dx.doi.org/10.1002/hep4.1134

Ejemplares similares

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long‐term follow‐up study
por: Hagström, Hannes, et al.
Publicado: (2017)

Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
por: Kechagias, Stergios, et al.
Publicado: (2022)

Repeated measurements of non‐invasive fibrosis tests to monitor the progression of non‐alcoholic fatty liver disease: A long‐term follow‐up study
por: Balkhed, Wile, et al.
Publicado: (2022)

Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms
por: Lykiardopoulos, Byron, et al.
Publicado: (2016)

Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD
por: Blomdahl, Julia, et al.
Publicado: (2023)

Effect of common genetic variants on the risk of cirrhosis in non‐alcoholic fatty liver disease during 20 years of follow‐up
por: Holmer, Magnus, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease does not increase dementia risk although histology data might improve risk prediction
por: Shang, Ying, et al.
Publicado: (2020)

Cost-effectiveness analysis of noninvasive tests to identify advanced fibrosis in non-alcoholic fatty liver disease
por: Gruneau, Lina, et al.
Publicado: (2023)

Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease
por: Qadri, Sami, et al.
Publicado: (2021)

Model-inferred mechanisms of liver function from magnetic resonance imaging data: Validation and variation across a clinically relevant cohort
por: Forsgren, Mikael F., et al.
Publicado: (2019)

Pinworm Infestation Mimicking Crohns' Disease
por: Johansson, Joel, et al.
Publicado: (2013)

History of Nonalcoholic Fatty Liver Disease
por: Lonardo, Amedeo, et al.
Publicado: (2020)

Automated quantification of steatosis: agreement with stereological point counting
por: Homeyer, André, et al.
Publicado: (2017)

Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies
por: Akuta, Norio, et al.
Publicado: (2017)

Combination Therapies for Nonalcoholic Fatty Liver Disease
por: Makri, Evangelia S., et al.
Publicado: (2022)

Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history
por: Magrì, Salvatore, et al.
Publicado: (2019)

Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach
por: Grgurevic, Ivica, et al.
Publicado: (2020)

Evaluating the prevalence and severity of NAFLD in primary care: the EPSONIP study protocol
por: Nasr, Patrik, et al.
Publicado: (2021)

Innate immunity and nonalcoholic fatty liver disease
por: Kountouras, Jannis, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation
por: Brunt, Elizabeth M.
Publicado: (2017)

New Perspectives in Pediatric Nonalcoholic Fatty Liver Disease: Epidemiology, Genetics, Diagnosis, and Natural History
por: Ko, Jae Sung
Publicado: (2019)

Littoral Cell Angioma in a Patient with Crohn's Disease
por: Johansson, Joel, et al.
Publicado: (2015)

What’s Past Is Prologue: History of Nonalcoholic Fatty Liver Disease
por: Targher, Giovanni
Publicado: (2020)

The role of noninvasive tests and liver biopsy in the diagnosis of nonalcoholic fatty liver disease
por: Isabela Andronescu, Craita, et al.
Publicado: (2018)

Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease
por: Kaya, Eda, et al.
Publicado: (2022)

Prevalence of biopsy-proven nonalcoholic fatty liver among patients with gallstone disease
por: Alsaif, Faisal A., et al.
Publicado: (2020)

Feasibility and Stability of Liver Biopsy before Treatment for Preclinical Nonalcoholic Fatty Liver Studies
por: Chae, Yeon Ji, et al.
Publicado: (2019)

The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease
por: Vachliotis, Ilias D., et al.
Publicado: (2023)

Assessing the disease burden of non-alcoholic fatty liver disease in the real world – big data and big numbers
por: Schattenberg, Jörn M., et al.
Publicado: (2019)

Hepatic patatin‐like phospholipase domain‐containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans
por: Ericson, Elke, et al.
Publicado: (2022)

Interobserver Agreement on Pathologic Features of Liver Biopsy Tissue in Patients with Nonalcoholic Fatty Liver Disease
por: Jung, Eun Sun, et al.
Publicado: (2016)

Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2019)

Serum Metabolites Are Associated With HFpEF in Biopsy‐Proven Nonalcoholic Fatty Liver Disease
por: Wegermann, Kara, et al.
Publicado: (2023)

Outcomes following Serial Intragastric Balloon Therapy for Obesity and Nonalcoholic Fatty Liver Disease in a Single Centre
por: Nguyen, Vi, et al.
Publicado: (2017)

Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)
por: Polyzos, Stergios A., et al.
Publicado: (2020)

Visual assessment of biliary excretion of Gd-EOB-DTPA in patients with suspected diffuse liver disease – A biopsy-verified prospective study
por: Norén, Bengt, et al.
Publicado: (2015)

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2021)

Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
por: Raptis, Dimitrios D, et al.
Publicado: (2023)

Tumor Necrosis Factor-Alpha and Adiponectin in Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma
por: Vachliotis, Ilias D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cjscalcdk5h59rjt528cvb4iau